8-K current report · filed Aug 13, 2026

Gossamer Bio, Inc. (GOSS) 8-K Current Report: August 13, 2026

Item 2.02Item EX-99.1GOSS overview

Short answer

Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.

Gossamer Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026
  • Press release attached as Exhibit 99.1, containing detailed results
  • Disclosure furnished under Regulation FD, not treated as filed under Exchange Act Section 18

Item EX-99.1 · Exhibit EX-99.1

  • FDA minutes support September 2026 NDA submission for seralutinib, with potential approval decision in Q3 2027 if accepted
  • Worldwide seralutinib rights reacquired from Chiesi, adding full control and economics while requiring capped royalties and milestones
  • Cash and marketable securities $57.0M, funding operations into Q1 2027 and highlighting near-term financing risk
  • Debt reduced $115.9M through exchange, but new $65.2M 7.50% secured notes due 2030 remain
  • Q2 net income $16.9M benefited from $43.8M debt extinguishment gain, while operating loss remained $26.1M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Gossamer Bio, Inc. 8-K filings

Get the next GOSS 8-K as it lands

Follow GOSS for push alerts, or ask the research agent what this filing means.